撰文丨王聪 编辑丨王多鱼 排版丨水成文 构成生命遗传基础的 DNA 不仅仅是一长串二维的线性密码，它们必须在细胞内高度折叠成精妙的三维（3D）结。这种空间布局如何影响基因功能，又在地球生命数十亿年的生命演化中经历了怎样的变迁，目前仍不完全清楚。 2026 年 4 月 21 日，西安交通大学叶凯团队（车一卓为论文第一作者）在国际顶尖学术期刊 Cell 上发表了题为：The evolution of high-order genome architecture revealed from 1,000 species 的研究论文。 这项研究通过对跨越 38 亿年演化史的 1025 个物种进行大规模的 Hi-C 数据分析，首次系统描绘了高阶基因组架构的演化全景图，追踪了基因组组织的演化轨迹——早期的单细胞生命形式大多呈现出随机的基因组结构。在整个植物演化过程中，全局折叠（染色体组型的空间组织）结构成为并一直保持着主要的形态结构。而动物逐渐发展出了更为明显的棋盘格（染色质区室的空间组织）结构；这些结构在早期胚胎发育过程中也很明显，这表明它们是一种保守的基因调控机制。相比之下，植物表现出相对较弱的

Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in JuneSAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that the American Society of Clinical Oncology (ASCO) has accepted an abstract for presentation at the 2026 ASCO An

Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics, today announced all submitted abstracts have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA. The four oral presentations will inc

Reports strong PBT margin growth of 10.7% QoQ and 20.9% YoY BANGALORE, India, April 21, 2026 /PRNewswire/ -- Tata Elxsi (BSE: 500408) (NSE: TATAELXSI), amongst the world's leading providers of design led technology services, announced its fourth quarter results for the period ending 31st March 2026. For the fourth quarter of financial year 2025-26, the company reported operating revenue of Rs. 993.8 Cr. while the full year revenue was Rs. 3,757.4 Cr. Highlights of the Quarter Ended 31st March 20

Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer and Simcere Zaiming Pharmaceutical Co., Ltd., (Simcere) an oncology-focused biopharmaceutical company and a subsidiary of Simcere Pharmaceutical Group Ltd (HKEX: 2096), toda

Roche Pharmaceuticals chief Teresa Graham has pinned 500 million Swiss francs in peak sales on a MOGAD expansion for Enspryng. The era of off-label guesswork for patients living with the rare autoimmune disorder MOGAD may soon be over, as a phase 3 victory for Roche’s Enspryng suggests a first-of-its-kind FDA approval may not be far away.Data from the phase 3 Meteoroid trial—the first randomized-controlled trial in this space—showed that Enspryng (satralizumab) reduced the risk of a MOGA

DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers, today announced the acceptance of an abstract “Early results from the first-in-human phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051)” at the 2026 American Society of Clin

SOUTH SAN FRANCISCO, Calif., April 21, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, today announced they have been selected for a late-breaking abstract (LBA) oral presentation to provide the complete data from the Phase 2/3 registrational trial (OptimUM-02) of darovasertib in combination with crizotinib in first-line (1L) HLA*A2-negative metastatic uveal melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeti

MUNICH--(BUSINESS WIRE)--Tubulis today announced that an abstract covering current clinical trial data from its ongoing Phase I/IIa NAPISTAR 1-01 trial (NCT06303505) has been accepted for a rapid oral presentation at the upcoming American Society of Clinical Oncology (ASCO) Meeting, being held May 29 - June 2, 2026, in Chicago. The presentation by Prof. Dr. Toon Van Gorp, clinical investigator of the study, will provide an update of maturing data from the ongoing dose escalation part of the ovar

The 22nd annual event convened nearly 500 attendees from 13 countries, featuring insightful scientific presentations, panels, and a keynote session by 18th U.S. Surgeon General Dr. Regina Benjamin, following a groundbreaking medical student breakfast program. CHICAGO, April 21, 2026 /PRNewswire/ -- The Skin of Color Society (SOCS), the world's leading professional society dedicated to advancing skin of color dermatology, successfully presented its 22nd Annual Scientific Symposium, "Championing